ArticleVaccines2021
Immuno-Informatics Analysis of Pakistan-Based HCV Subtype-3a for Chimeric Polypeptide Vaccine Design.
Article in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- A meta-analysis: the efficacy and effectiveness of polypeptide vaccines protect pigs from foot and mouth disease.Scientific reports · 2022Pooled it
- Immunopharmacological design of a multi-epitope vaccine targeting hepatitis C virus genotype 3a.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Computational design of a novel multi-epitope vaccine candidate against group A rotavirus.Virology journal · 2026Article
- Multi-epitope vaccine design against human metapneumovirus via reverse vaccinology and molecular modelling.Scientific reports · 2025Article
- Immuno-informatics analyses of important esophageal cancer associated viruses for multi-epitope vaccine design.Frontiers in immunology · 2025Article
- Development of a potential vaccine against Capripox virus implementing reverse vaccinology and pan-genomic immunoinformatics.PloS one · 2025Article
- Proteome-Wide Screening of Potential Vaccine Targets againstVaccines · 2023Article
- Mapping Potential Vaccine Candidates Predicted by VaxiJen for Different Viral Pathogens between 2017-2021-A Scoping Review.Vaccines · 2022Article
- In silico designing of a novel epitope-based candidate vaccine against Streptococcus pneumoniae with introduction of a new domain of PepO as adjuvant.Journal of translational medicine · 2022Article
- Article
- Whole Proteome-Based Therapeutic Targets Annotation and Designing of Multi-Epitope-Based Vaccines against the Gram-Negative XDR-Vaccines · 2022Article
- Immunomodulatory and Allergenic Properties of Antimicrobial Peptides.International journal of molecular sciences · 2022Review
- Designing a Recombinant Vaccine againstVaccines · 2022Article
- Article
- Proteome-Wide and Protein-Specific Multi-Epitope Vaccine Constructs Against the Rift Valley Fever Virus Outbreak Using Integrated Omics Approaches.Frontiers in microbiology · 2022Article
- Immunoinformatics Approach Toward the Introduction of a Novel Multi-Epitope Vaccine AgainstFrontiers in immunology · 2022Article
- Allergic Diseases: A Comprehensive Review on Risk Factors, Immunological Mechanisms, Link with COVID-19, Potential Treatments, and Role of Allergen Bioinformatics.International journal of environmental research and public health · 2021Review
- Molecular Insights into Binding Mode and Interactions of Structure-Based Virtually Screened Inhibitors forMolecules (Basel, Switzerland) · 2021Article
- An integrated computational framework to design a multi-epitopes vaccine against Mycobacterium tuberculosis.Scientific reports · 2021Article
- In Silico Core Proteomics and Molecular Docking Approaches for the Identification of Novel Inhibitors againstInternational journal of environmental research and public health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV) causes chronic and acute hepatitis infections. As there is extreme variability in the HCV genome, no approved HCV vaccine has been available so far. An effective polypeptide vaccine based on the functionally conserved epitopes will be greatly helpful in curing disease. For this purpose, an immuno-informatics study is performed based on the published HCV subtype-3a from Pakistan. First, the virus genome was translated to a polyprotein followed by a subsequent prediction of T-cell epitopes. Non-allergenic, IFN-γ producer, and antigenic epitopes were shortlisted, including 5 HTL epitopes and 4 CTL, which were linked to the final vaccine by GPGPG and AAY linkers, respectively. Beta defensin was included as an adjuvant through the EAAAK linker to improve the immunogenicity of the polypeptide. To ensure its safety and immunogenicity profile, antigenicity, allergenicity, and various physiochemical attributes of the polypeptide were evaluated. Molecular docking was conducted between TLR4 and vaccine to evaluate the binding affinity and molecular interactions. For stability assessment and binding of the vaccine-TLR4 docked complex, molecular dynamics (MD) simulation and MMGBSA binding free-energy analyses were conducted. Finally, the candidate vaccine was cloned in silico to ensure its effectiveness. The current vaccine requires future experimental confirmation to validate its effectiveness. The vaccine construct produced might be useful in providing immune protection against HCV-related infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.